GLP-3 is a novel investigational peptide that functions as a triple agonist, targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. This multi-receptor activity is designed to enhance metabolic regulation by improving insulin sensitivity, reducing appetite, increasing energy expenditure, and promoting weight reduction.

In research settings, GLP-3 has been studied for its ability to deliver greater efficacy in weight management and glycemic control compared to single- or dual-agonist therapies. By engaging three distinct pathways, GLP-3 may provide synergistic benefits for metabolic health, making it a key focus in obesity and type 2 diabetes research.

Potential applications of GLP-3 peptide research include:

✔ Weight management studies with superior reductions in body fat and appetite suppression

✔ Type 2 diabetes research focused on glycemic control and insulin sensitivity

✔ Metabolic health studies exploring energy expenditure and improved lipid profiles

✔ Cardiovascular risk reduction research through comprehensive metabolic regulation

RETATRUTIDE COA 1
RETATRUTIDE COA 2